Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies

References

• Nagorsen D, Bargou R, Ruttinger D, Kufer P, Baeuerle PA, Zugmaier G. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leukemia & lymphoma. 2009;50:886–91. doi:10.1080/10428190902943077.
   PubMed Web of Science ®Google Scholar
• McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Molecular cancer therapeutics. 2012;11:582–93. doi:10.1158/1535-7163.MCT-11-0820.
   PubMed Web of Science ®Google Scholar
• Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. mAbs. 2011;3:273–88. doi:10.4161/mabs.3.3.15188.
   PubMed Web of Science ®Google Scholar
• Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliott JM, Prabhu S, Watts RJ, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med. 2011;3:84ra44. doi:10.1126/scitranslmed.3002230.
   PubMed Web of Science ®Google Scholar
• Mazor Y, Oganesyan V, Yang C, Hansen A, Wang J, Liu H, Sachsenmeier K, Carlson M, Gadre DV, Borrok MJ, et al. Improving target cell specificity using a novel monovalent bispecific IgG design. mAbs. 2015;7:377–89. doi:10.1080/19420862.2015.1007816.
   PubMed Web of Science ®Google Scholar
• Nisonoff A, Rivers MM. Recombination of a mixture of univalent antibody fragments of different specificity. Archives of biochemistry and biophysics. 1961;93:460–2. doi:10.1016/0003-9861(61)90296-X.
   PubMedGoogle Scholar
• Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Molecular immunology. 2015;67:95–106. doi:10.1016/j.molimm.2015.01.003.
   PubMed Web of Science ®Google Scholar
• Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D, Clark V, Hristopoulos M, Cook R, Slaga D, et al. Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing. Cancer cell. 2017;31:383–95. doi:10.1016/j.ccell.2017.02.001.
   PubMed Web of Science ®Google Scholar
• White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, Penfold CA, Booth SG, Dodhy A, Polak ME, et al. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer cell. 2015;27:138–48. doi:10.1016/j.ccell.2014.11.001.
   PubMed Web of Science ®Google Scholar
• Jost C, Schilling J, Tamaskovic R, Schwill M, Honegger A, Pluckthun A. Structural basis for eliciting a cytotoxic effect in HER2-overexpressing cancer cells via binding to the extracellular domain of HER2. Structure. 2013;21:1979–91. doi:10.1016/j.str.2013.08.020.
   PubMed Web of Science ®Google Scholar
• Moraga I, Wernig G, Wilmes S, Gryshkova V, Richter CP, Hong WJ, Sinha R, Guo F, Fabionar H, Wehrman TS, et al. Tuning cytokine receptor signaling by re-orienting dimer geometry with surrogate ligands. Cell. 2015;160:1196–208. doi:10.1016/j.cell.2015.02.011.
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Igawa T, Sampei Z, Muto A, Kojima T, Soeda T, Yoshihashi K, Okuyama-Nishida Y, Saito H, Tsunoda H, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nature medicine. 2012;18:1570–4. doi:10.1038/nm.2942.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. mAbs. 2017:9:182–212.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:5145–50. doi:10.1073/pnas.1220145110.
   PubMed Web of Science ®Google Scholar
• Spiess C, Merchant M, Huang A, Zheng Z, Yang NY, Peng J, Ellerman D, Shatz W, Reilly D, Yansura DG, et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nature biotechnology. 2013;31:753–8. doi:10.1038/nbt.2621.
   PubMed Web of Science ®Google Scholar
• Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. Journal of molecular biology. 2012;420:204–19. doi:10.1016/j.jmb.2012.04.020.
   PubMed Web of Science ®Google Scholar
• Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nature biotechnology. 2014;32:191–8. doi:10.1038/nbt.2797.
   PubMed Web of Science ®Google Scholar
• Fischer N, Elson G, Magistrelli G, Dheilly E, Fouque N, Laurendon A, Gueneau F, Ravn U, Depoisier JF, Moine V, et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nature communications. 2015;6:6113. doi:10.1038/ncomms7113.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Meesters JI, Priem P, de Jong RN, van den Bremer ET, van Kampen MD, et al. Controlled Fab-arm exchange for the generation of stable bispecific IgG1. Nature protocols. 2014;9:2450–63. doi:10.1038/nprot.2014.169.
   PubMed Web of Science ®Google Scholar
• Dillon M, Yin Y, Zhou J, McCarty L, Ellerman D, Slaga D, et al. Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells. mAbs. 2017;9:213–30.
   Web of Science ®Google Scholar
• Liu Z, Leng EC, Gunasekaran K, Pentony M, Shen M, Howard M, Stoops J, Manchulenko K, Razinkov V, Liu H, et al. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. The Journal of biological chemistry. 2015;290:7535–62. doi:10.1074/jbc.M114.620260.
   PubMed Web of Science ®Google Scholar
• Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, et al. An efficient route to human bispecific IgG. Nature biotechnology. 1998;16:677–81. doi:10.1038/nbt0798-677.
   PubMed Web of Science ®Google Scholar
• Sharkey B, Pudi S, Wallace Moyer I, Zhong L, Prinz B, Baruah H, et al. Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients. mAbs. 2017;9:257–68.
   Web of Science ®Google Scholar
• Ward ES. VH shuffling can be used to convert an Fv fragment of anti-hen egg lysozyme specificity to one that recognizes a T cell receptor V alpha. Molecular immunology. 1995;32:147–56. doi:10.1016/0161-5890(94)00119-L.
   PubMed Web of Science ®Google Scholar
• Krah S, Schroter C, Eller C, Rhiel L, Rasche N, Beck J, et al. Generation of human bispecific common light chain antibodies by combining animal immunization and yeast display. Protein Eng Des Sel. 2017;30:291–301. doi:10.1093/protein/gzw077.
   PubMed Web of Science ®Google Scholar
• Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, et al. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. The Journal of biological chemistry. 2010;285:20850–9. doi:10.1074/jbc.M110.113910.
   PubMed Web of Science ®Google Scholar
• Nissim A, Hoogenboom HR, Tomlinson IM, Flynn G, Midgley C, Lane D, et al. Antibody fragments from a ‘single pot’ phage display library as immunochemical reagents. The EMBO journal. 1994;13:692–8.
   PubMed Web of Science ®Google Scholar
• Smith EJ, Olson K, Haber LJ, Varghese B, Duramad P, Tustian AD, et al. A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys. Scientific reports. 2015;5:17943. doi:10.1038/srep17943.
   PubMed Web of Science ®Google Scholar
• Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nature biotechnology. 2005;23:1126–36. doi:10.1038/nbt1142.
   PubMed Web of Science ®Google Scholar
• Tiller T, Schuster I, Deppe D, Siegers K, Strohner R, Herrmann T, et al. A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties. mAbs. 2013;5:445–70. doi:10.4161/mabs.24218.
   PubMed Web of Science ®Google Scholar
• Glanville J, Zhai W, Berka J, Telman D, Huerta G, Mehta GR, et al. Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proceedings of the National Academy of Sciences of the United States of America. 2009;106:20216–21. doi:10.1073/pnas.0909775106.
   PubMed Web of Science ®Google Scholar
• DeKosky BJ, Kojima T, Rodin A, Charab W, Ippolito GC, Ellington AD, et al. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nature medicine. 2015;21:86–91. doi:10.1038/nm.3743.
   PubMed Web of Science ®Google Scholar
• Chothia C, Lesk AM. Canonical structures for the hypervariable regions of immunoglobulins. Journal of molecular biology. 1987;196:901–17. doi:10.1016/0022-2836(87)90412-8.
   PubMed Web of Science ®Google Scholar
• Rothlisberger D, Honegger A, Pluckthun A. Domain interactions in the Fab fragment: a comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. Journal of molecular biology. 2005;347:773–89. doi:10.1016/j.jmb.2005.01.053.
   PubMed Web of Science ®Google Scholar
• Ewert S, Huber T, Honegger A, Pluckthun A. Biophysical properties of human antibody variable domains. Journal of molecular biology. 2003;325:531–53. doi:10.1016/S0022-2836(02)01237-8.
   PubMed Web of Science ®Google Scholar
• Raghunathan G, Smart J, Williams J, Almagro JC. Antigen-binding site anatomy and somatic mutations in antibodies that recognize different types of antigens. Journal of molecular recognition: JMR. 2012;25:103–13. doi:10.1002/jmr.2158.
   PubMed Web of Science ®Google Scholar
• Zhai W, Glanville J, Fuhrmann M, Mei L, Ni I, Sundar PD, et al. Synthetic antibodies designed on natural sequence landscapes. Journal of molecular biology. 2011;412:55–71. doi:10.1016/j.jmb.2011.07.018.
   PubMed Web of Science ®Google Scholar
• Van den Brulle J, Fischer M, Langmann T, Horn G, Waldmann T, Arnold S, et al. A novel solid phase technology for high-throughput gene synthesis. BioTechniques. 2008;45:340–3. doi:10.2144/000112953.
   PubMed Web of Science ®Google Scholar
• Fath S, Bauer AP, Liss M, Spriestersbach A, Maertens B, Hahn P, et al. Multiparameter RNA and codon optimization: a standardized tool to assess and enhance autologous mammalian gene expression. PloS one. 2011;6:e17596. doi:10.1371/journal.pone.0017596.
   PubMed Web of Science ®Google Scholar
• Maertens B, Spriestersbach A, von Groll U, Roth U, Kubicek J, Gerrits M, et al. Gene optimization mechanisms: a multi-gene study reveals a high success rate of full-length human proteins expressed in Escherichia coli. Protein Sci. 2010;19:1312–26. doi:10.1002/pro.408.
   PubMed Web of Science ®Google Scholar
• Miersch S, Sidhu SS. Synthetic antibodies: concepts, potential and practical considerations. Methods. 2012;57:486–98. doi:10.1016/j.ymeth.2012.06.012.
   PubMed Web of Science ®Google Scholar
• Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, et al. Biophysical properties of the clinical-stage antibody landscape. Proceedings of the National Academy of Sciences of the United States of America. 2017;114:944–9. doi:10.1073/pnas.1616408114.
   Web of Science ®Google Scholar
• Lee CV, Sidhu SS, Fuh G. Bivalent antibody phage display mimics natural immunoglobulin. Journal of immunological methods. 2004;284:119–32. doi:10.1016/j.jim.2003.11.001.
   PubMed Web of Science ®Google Scholar
• Fagerstam LG, Frostell A, Karlsson R, Kullman M, Larsson A, Malmqvist M, et al. Detection of antigen-antibody interactions by surface plasmon resonance. Application to epitope mapping. Journal of molecular recognition: JMR. 1990;3:208–14. doi:10.1002/jmr.300030507.
   PubMedGoogle Scholar
• Abdiche YN, Harriman R, Deng X, Yeung YA, Miles A, Morishige W, et al. Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms. mAbs. 2016;8:264–77. doi:10.1080/19420862.2015.1118596.
   PubMed Web of Science ®Google Scholar
• Xu JL, Davis MM. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity. 2000;13:37–45. doi:10.1016/S1074-7613(00)00006-6.
   PubMed Web of Science ®Google Scholar
• Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu TY, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel. 2013;26:663–70. doi:10.1093/protein/gzt047.
   PubMed Web of Science ®Google Scholar
• Prassler J, Steidl S, Urlinger S. In vitro affinity maturation of HuCAL antibodies: complementarity determining region exchange and RapMAT technology. Immunotherapy. 2009;1:571–83.
   PubMed Web of Science ®Google Scholar
• Clackson T, Hoogenboom HR, Griffiths AD, Winter G. Making antibody fragments using phage display libraries. Nature. 1991;352:624–8. doi:10.1038/352624a0.
   PubMed Web of Science ®Google Scholar
• Kang AS, Jones TM, Burton DR. Antibody redesign by chain shuffling from random combinatorial immunoglobulin libraries. Proceedings of the National Academy of Sciences of the United States of America. 1991;88:11120–3. doi:10.1073/pnas.88.24.11120.
   PubMed Web of Science ®Google Scholar
• Sidhu SS, Lowman HB, Cunningham BC, Wells JA. Phage display for selection of novel binding peptides. Methods in enzymology. 2000;328:333–63. doi:10.1016/S0076-6879(00)28406-1.
   PubMed Web of Science ®Google Scholar
• Cheuk AT, Mufti GJ, Guinn BA. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer gene therapy. 2004;11:215–26. doi:10.1038/sj.cgt.7700670.
   PubMed Web of Science ®Google Scholar
• Fisher TS, Kamperschroer C, Oliphant T, Love VA, Lira PD, Doyonnas R, et al. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer immunology, immunotherapy: CII. 2012;61:1721–33. doi:10.1007/s00262-012-1237-1.
   PubMed Web of Science ®Google Scholar
• Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nature medicine. 1997;3:682–5. doi:10.1038/nm0697-682.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Sznol M, Hu-Lieskovan S, Papadopoulos KP, Patnaik A, Rasco DW, et al. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Clinical cancer research: an official journal of the American Association for Cancer Research. 2017;23:5349–57. doi:10.1158/1078-0432.CCR-17-1243.
   Web of Science ®Google Scholar
• Wakefield I, Stephens S, Foulkes R, Nesbitt A, Bourne T. The use of surrogate antibodies to evaluate the developmental and reproductive toxicity potential of an anti-TNFalpha PEGylated Fab' monoclonal antibody. Toxicological sciences: an official journal of the Society of Toxicology. 2011;122:170–6. doi:10.1093/toxsci/kfr083.
   PubMed Web of Science ®Google Scholar
• Zeder-Lutz G, Zuber E, Witz J, Van Regenmortel MH. Thermodynamic analysis of antigen-antibody binding using biosensor measurements at different temperatures. Anal Biochem. 1997;246:123–32. doi:10.1006/abio.1996.9999.
   PubMed Web of Science ®Google Scholar
• Ridgway JB, Presta LG, Carter P. ‘Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996;9:617–21. doi:10.1093/protein/9.7.617.
   PubMedGoogle Scholar
• Labrijn AF, Meesters JI, Bunce M, Armstrong AA, Somani S, Nesspor TC, et al. Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models. Scientific reports. 2017;7:2476. doi:10.1038/s41598-017-02823-9.
   PubMed Web of Science ®Google Scholar
• Sockolosky JT, Dougan M, Ingram JR, Ho CC, Kauke MJ, Almo SC, et al. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proceedings of the National Academy of Sciences of the United States of America. 2016;113:E2646–54. doi:10.1073/pnas.1604268113.
   PubMed Web of Science ®Google Scholar
• Perez-Ruiz E, Etxeberria I, Rodriguez-Ruiz ME, Melero I. Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2017;23:5326–8. doi:10.1158/1078-0432.CCR-17-1799.
   PubMed Web of Science ®Google Scholar
• Sidhu SS, Li B, Chen Y, Fellouse FA, Eigenbrot C, Fuh G. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. Journal of molecular biology. 2004;338:299–310. doi:10.1016/j.jmb.2004.02.050.
   PubMed Web of Science ®Google Scholar
• Yoo D, Provchy J, Park C, Schulz C, Walker K. Automated high-throughput protein purification using an AKTApurifier and a CETAC autosampler. Journal of chromatography A. 2014;1344:23–30. doi:10.1016/j.chroma.2014.04.014.
   PubMed Web of Science ®Google Scholar
• Safsten P, Klakamp SL, Drake AW, Karlsson R, Myszka DG. Screening antibody-antigen interactions in parallel using Biacore A100. Anal Biochem. 2006;353:181–90. doi:10.1016/j.ab.2006.01.041.
   PubMed Web of Science ®Google Scholar